SARS-CoV-2 and Androgenic Alopecia: Exploring Links

January 2021 in “ International Journal of Dermatology ”

Mir Ibrahim Sajid, Dur-E Najaf, Ayesha Tariq Niaz, Samira Shabbir Balouch, Sajid Abaidullah

androgenic alopecia androgen receptor ACE-2 TMPRSS2 SARS-CoV-2 AA COVID-19

TLDR Possible link between COVID-19 and hair loss; more research needed.

Several articles explore the potential links between SARS-CoV-2 and androgenic alopecia (AA), a type of hair loss. Studies suggest that androgen receptor activity may play a role in the transcription and regulation of ACE-2 and TMPRSS2, potentially contributing to the development of androgenic alopecia in COVID-19 patients. The prevalence of AA was found to be higher in female patients aged over 69 years who were diagnosed with SARS-CoV-2. Clinicians and dermatologists should counsel their patients and raise awareness to decrease the mental burden in an already stress-prevalent time. Further research is needed to fully understand the potential link between androgenic alopecia and COVID-19.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Cited in this study

7 / 7 results

research Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign'

119 citations , August 2020 in “Journal of The American Academy of Dermatology”

Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.

research Spironolactone: An Anti-Androgenic and Anti-Hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

36 citations , July 2020 in “Frontiers in Medicine”

Spironolactone might help protect against severe lung problems in COVID-19 patients.

research Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19

70 citations , July 2020 in “Pharmacological Reports”

Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.

research Evaluation of the Effects of COVID-19 Pandemic on Hair Diseases Through a Web-Based Questionnaire

39 citations , July 2020 in “Dermatologic Therapy”

The COVID-19 pandemic led to an increase in untreated hair diseases and showed the importance of teledermatology.

research A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity

134 citations , July 2020 in “Journal of Cosmetic Dermatology”

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

research Androgen Sensitivity Gateway to COVID-19 Disease Severity

123 citations , May 2020 in “Drug Development Research”

Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.

research Potential Targets in the Discovery of New Hair Growth Promoters for Androgenic Alopecia

59 citations , June 2014 in “Expert Opinion on Therapeutic Targets”

The document concludes that targeting 5α-reductase, the androgen receptor, and hair growth genes, along with using compounds with anti-androgenic properties, could lead to more effective hair loss treatments.